Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C

Li,Jun‑Feng; Qu,Feng; Zheng,Su‑Jun; Ren,Feng; Wu,Hui‑Li; Liu,Mei; Ren,Jin‑Yu; Chen,Yu; Duan,Zhong‑Ping; Zhang,Jin‑Lan

doi:10.3892/mmr.2015.3361

July-2015 Volume 12 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2015 Volume 12 Issue 1

Full Size Image

Article

Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C

Authors:
- Jun‑Feng Li
- Feng Qu
- Su‑Jun Zheng
- Feng Ren
- Hui‑Li Wu
- Mei Liu
- Jin‑Yu Ren
- Yu Chen
- Zhong‑Ping Duan
- Jin‑Lan Zhang
View Affiliations / Copyright

Affiliations: The First Clinical Medical School, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China, Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, P.R. China, Evergreen Wellness Center, Kansas College of Chinese Medicine, Wichita, Kansas 67207, USA
Pages: 323-330
|
Published online on: February 17, 2015

https://doi.org/10.3892/mmr.2015.3361
Expand metrics +

Abstract

The plasma profile of sphingolipids in hepatic fibrosis patients with chronic hepatitis C (CHC) is rarely considered at present. The association between plasma sphingolipids and severe fibrosis in CHC remains an obscure area of research. The aim of the present study was to assess the plasma profile of sphingolipids and to examine the association between plasma sphingolipids and severe fibrosis in CHC, in order to identify potential novel markers of severe fibrosis in CHC. A cohort of 120 treatment‑naïve patients with CHC were included in the present study. Liver biopsies were performed and routine serological indicators were measured. Plasma sphingolipids were detected using high performance liquid chromatography tandem mass spectrometry. A total of 44 plasma sphingolipids were detected. Plasma hexosylceramide (HexCer; d18:1/12:0), HexCer (d18:1/16:0) and HexCer (d18:1/22:0) were shown to be significantly different in patients with CHC between those with and without severe fibrosis (Metavir F ≥3; P<0.05). HexCer (d18:1/12:0) was observed to be closely associated with severe fibrosis in CHC [odds ratio (OR)=1.03] following adjustment for confounding variables in a multivariate analysis. HexCer (d18:1/12:0) had diagnostic value for severe fibrosis in CHC [area under the curve (AUC)=0.69]. In patients with CHC who had developed significant fibrosis (Metavir F ≥2), HexCer (d18:1/12:0) remained closely associated with severe fibrosis (OR=1.08) in this subgroup. In addition, HexCer (d18:1/12:0) had sufficient diagnostic ability (AUC=0.73) to distinguish severe fibrosis in patients with CHC with significant fibrosis. In conclusion, the present study indicated that plasma HexCer (d18:1/12:0) exhibits a close correlation with severe hepatic fibrosis in CHC, particularly in patients who have significant fibrosis. Additionally, HexCer (d18:1/12:0) may be a potential marker of severe hepatic fibrosis in CHC.

View Figures

View References

1	Mohd Hanafiah K, Groeger J, Flaxman AD and Wiersma ST: Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 57:1333–1342. 2013. View Article : Google Scholar
2	Ghany MG, Strader DB, Thomas DL and Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 49:1335–1374. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lawson A, Hagan S, Rye K, et al: The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol. 47:37–45. 2007. View Article : Google Scholar : PubMed/NCBI
4	Sebastiani G and Alberti A: How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 19(Suppl 1): 18–32. 2012. View Article : Google Scholar : PubMed/NCBI
5	Regev A, Berho M, Jeffers LJ, et al: Sampling error and intrao-bserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 97:2614–2618. 2002. View Article : Google Scholar : PubMed/NCBI
6	Lingwood D and Simons K: Lipid rafts as a membrane-organizing principle. Science. 327:46–50. 2010. View Article : Google Scholar : PubMed/NCBI
7	Milhas D, Clarke CJ and Hannun YA: Sphingomyelin metabolism at the plasma membrane: implications for bioactive sphingolipids. FEBS Lett. 584:1887–1894. 2010. View Article : Google Scholar :
8	Bartke N and Hannun YA: Bioactive sphingolipids: metabolism and function. J Lipid Res. 50(Suppl): S91–S96. 2009. View Article : Google Scholar :
9	Sakamoto H, Okamoto K, Aoki M, et al: Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol. 1:333–337. 2005. View Article : Google Scholar
10	Umehara T, Sudoh M, Yasui F, et al: Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun. 346:67–73. 2006. View Article : Google Scholar : PubMed/NCBI
11	Shea BS and Tager AM: Sphingolipid regulation of tissue fibrosis. Open Rheumatol J. 6:123–129. 2012. View Article : Google Scholar : PubMed/NCBI
12	Strub GM, Maceyka M, Hait NC, Milstien S and Spiegel S: Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol. 688:141–155. 2010.PubMed/NCBI
13	Li C, Zheng S, You H, et al: Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol. 54:1205–1213. 2011. View Article : Google Scholar
14	Ikeda H, Ohkawa R, Watanabe N, et al: Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. Clin Chim Acta. 411:765–770. 2010. View Article : Google Scholar : PubMed/NCBI
15	Qu F, Wu CS, Hou JF, Jin Y and Zhang JL: Sphingolipids as new biomarkers for assessment of delayed-type hypersensitivity and response to triptolide. PLoS One. 7:e524542012. View Article : Google Scholar
16	Qu F, Zheng SJ, Wu CS, Jia ZX, Zhang JL and Duan ZP: Lipidomic profiling of plasma in patients with chronic hepatitis C infection. Anal Bioanal Chem. 406:555–564. 2014. View Article : Google Scholar
17	Hepatotogy Branch, Infectious and Parasitology branch, Chinese Medical Association: Guideline of prevention and treatment of hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi. 38:210–215. 2004.
18	Group TFMCS Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 20:15–20. 1994. View Article : Google Scholar
19	Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 24:289–293. 1996. View Article : Google Scholar : PubMed/NCBI
20	Park O, Jeong WI, Wang L, et al: Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology. 49:1683–1694. 2009. View Article : Google Scholar : PubMed/NCBI
21	Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatology. 31:1014–1018. 2000. View Article : Google Scholar : PubMed/NCBI
22	Yano M, Kumada H, Kage M, et al: The long-term pathological evolution of chronic hepatitis C. Hepatology. 23:1334–1340. 1996. View Article : Google Scholar : PubMed/NCBI
23	Marcellin P, Asselah T and Boyer N: Fibrosis and disease progression in hepatitis C. Hepatology. 36:S47–S56. 2002. View Article : Google Scholar : PubMed/NCBI